Clarity Pharmaceuticals

Australia - EveleighPharmaceutical5 H-1B visas (FY2023)

Focus: Clarity Pharmaceuticals specializes in radiopharmaceutical labeling, focusing on copper-64 and copper-67 labeled therapeutics for oncology and neurology. The company operates as a specialized biotech with a concentrated pipeline in targeted nuclear medicine.

Neurology

Profile data last refreshed 14h ago · AI intelligence enriched 2w ago

Open Jobs

Should You Work at Clarity Pharmaceuticals?

AI assessment

Strong fit for radiochemistry or nuclear medicine specialists seeking rare expertise and Phase 3 upside; poor fit for those prioritizing financial transparency, published science, or broad career mobility.

Why Work Here

Rare radiopharmaceutical expertise: Copper-64/67 labeling is a highly specialized niche with limited competition, offering deep technical differentiation and publication potential.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)

Vascular Death

N/A

VICTORY PATCH

Muscle Strength

N/A

Clinical Trials (1)

Help build intelligence for Clarity Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Phase 3 momentum: Two Phase 3 programs (64Cu-SAR-bisPSMA for prostate cancer) represent late-stage validation and upcoming regulatory catalysts within 2–3 years.

100% H1B approval rate (5/5 in 2023): Company demonstrates willingness to sponsor visa candidates and suggests strong financial stability to bear immigration costs.

Watch Out For

Opaque financials and headcount: Missing employee count, funding data, revenue, and cash position make it impossible to assess runway or restructuring risk—critical for biotech stability.
Minimal published output: Zero publications despite 14 active clinical programs suggests either early-stage data lock or underinvestment in scientific communication, limiting CV prestige.
Tiny current hiring (4 open roles, 3 IT + 1 Product): No visible career ladder; growth appears stalled outside core R&D, limiting advancement pathways for non-specialist functions.

Generated by Claude from Clarity Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06430879Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential

N/A

Counseling Sessions

Brain Tumor

N/A

Clinical Trials (1)

NCT05789862Behavioral Health Evaluation and Intervention Program for Patients Undergoing Craniotomy

N/A

PEACE Patch

Stress

N/A

Clinical Trials (1)

NCT06708715Stress Reduction After Use of a Haptic Vibrotactile Trigger Technology Patch: Analysis and Assessment

N/A

Audiovisual stimulation VR system

Healthy Aging

N/A

Clinical Trials (1)

NCT06234930The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation

N/A

Drug- free, non-invasive patch

Pain, Back

N/A

Clinical Trials (1)

NCT06505005Relieving Pain and Improving Sleep: Evaluating Topical Pain Relief and Sleep Patches

N/A

Virtual Reality Gamma Sensory Stimulation

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT07310862Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis

N/A

Follicle Clarity

Infertility, Female

N/A

Clinical Trials (1)

NCT04545918Convolutional Neural Network in Ovarian Follicle Identification

N/A

LIBERTY Patch

Fall Risk

N/A

Clinical Trials (1)

NCT07781397Prevention and Reduction of Falls: Testing and Evaluating Cutting Edge Haptic Technology

N/A

Victory Patch with Haptic Vibrotactile Trigger Technology

VO2max

N/A

Clinical Trials (1)

NCT07285252Evaluating Non-Invasive Haptics During Extreme Exercise

N/A

Objective Depth-of-Focus Changes During Light Adjustable Lens UV Adjustments

Light Adjustable Lens

N/A

Clinical Trials (1)

NCT07868003Objective Depth-of-Focus Changes During Light Adjustable Lens UV Adjustments

N/A

IGNITE Patch

Resting Metabolic Rate

N/A

Clinical Trials (1)

NCT07781384Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis

N/A

SuperPatch REM Patch

Shift Work Sleep Disorder

N/A

Clinical Trials (1)

NCT07785960Recovery and Early Sleep Tracking Using the SuperPatch REM Patch

N/A

64Cu-SARTATE

Neuroendocrine Tumors

Phase 1

Clinical Trials (1)

NCT04440956An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Phase 1

64Cu-SAR-bisPSMA

Prostatic Neoplasms

Phase 1

Clinical Trials (1)

NCT04839367Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Phase 1

Cu-64 SARTATE and Cu-67 SARTATE

Meningioma

Phase 1/2

Clinical Trials (1)

NCT03936426Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Phase 1/2

64Cu-SAR-bisPSMA

Prostate Cancer

Phase 1/2

Clinical Trials (1)

NCT0528684064Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Phase 1/2

67Cu-SARTATE

Neuroblastoma

Phase 1/2

Clinical Trials (1)

NCT0402333167Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Phase 1/2

64Cu-SAR-bisPSMA

Biochemical Recurrence of Malignant Neoplasm of Prostate

Phase 1/2

Clinical Trials (1)

NCT0524912764Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Phase 1/2

64Cu-SAR-BBN

Prostatic Neoplasms

Phase 1/2

Clinical Trials (1)

NCT0563316064Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Phase 1/2

64Cu-SAR-bisPSMA

Prostatic Neoplasms, Castration-Resistant

Phase 1/2

Clinical Trials (1)

NCT0486860464Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Phase 1/2

64Cu-SAR-BBN

Biochemical Recurrence of Malignant Neoplasm of Prostate

Phase 2

Clinical Trials (1)

NCT0540731164Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

Phase 2

Copper-64 labelled SAR-Bombesin

Prostate Cancer

Phase 2

Clinical Trials (1)

NCT05613842Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

Phase 2

64Cu-SARTATE

Neuroendocrine Tumors

Phase 2

Clinical Trials (1)

NCT04438304A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Phase 2

64Cu-SAR-bisPSMA

Prostate Cancer (Post Prostatectomy)

Phase 2

Clinical Trials (1)

NCT06907641Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Phase 2

64Cu-SAR-bisPSMA

Prostate Cancer

Phase 3

Clinical Trials (1)

NCT0697084764Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Phase 3

64Cu-SAR-bisPSMA

Prostate Cancer

Phase 3

Clinical Trials (1)

NCT06056830Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Phase 3

Interview Prep Quick Facts

Portfolio: 26 clinical trials

Top TAs: Oncology, Neurology, Women's Health

H-1B (2023): 5 approvals

Open Roles: 4 active jobs

Therapeutic Area Focus

Oncology

14 pipeline

Neurology

3 pipeline

Women's Health

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Clarity Pharmaceuticals

Should You Work at Clarity Pharmaceuticals?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (4)

GenAI Engineer

Senior Data Engineer

Web: Full Stack Tech Lead

Product Manager – Voice of the Customer

Hiring Trend

Visa Sponsorship